Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Movement Disorders

• Publication date

  2010-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.23254PMID 20737546
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?

  2009cited by this paper
• An open‐label, randomized, 64‐week study repeating 10‐ and 20‐U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects

  2009cited by this paper
• Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.

  2008cited by this paper
• Characterization of New Formalin-Detoxified Botulinum Neurotoxin Toxoids

  2008cited by this paper
• Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

  2008cited by this paper
• Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.

  2007cited by this paper
• Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke.

  2007cited by this paper
• Botulinum Toxin Type A Prophylactic Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Exploratory Study

  2006cited by this paper
• A review of WHO International Standards for botulinum antitoxins.

  2006cited by this paper
• Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

  2005cited by this paper
• Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2005cited by this paper
• Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

  2005cited by this paper
• Development of resistance to botulinum toxin type A in patients with torticollis

  2004cited by this paper
• Basic immunological aspects of botulinum toxin therapy

  2004cited by this paper
• Detection of antibodies against botulinum toxins

  2004influential reference
• A Randomized Double-blind Placebo-controlled Trial

  2004cited by this paper
• Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke

  2004cited by this paper
• Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.

  2003cited by this paper
• Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Botulinum Toxin Type A for Patients with Glabellar Lines

  2003cited by this paper
• Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

  2003cited by this paper
• A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.

  2002cited by this paper
• Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.

  2002cited by this paper
• Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial

  2001cited by this paper
• Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies

  1999cited by this paper
• Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical response

  1998cited by this paper
• Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

  1997cited by this paper
• Botulinum toxin therapy, immunologic resistance, and problems with available materials

  1996cited by this paper
• Response and immunoresistance to botulinum toxin injections

  1995cited by this paper
• Therapy with botulinum toxin

  1994cited by this paper
• Immunogenicity of the neurotoxins of Clostridium botulinum

  1994cited by this paper
• Change in pattern of muscle activity following botulinum toxin injections for torticollis

  1991cited by this paper

• A Novel Nonsurgical Smooth Thread Technique to Correct Gummy Smiles

  2025cites this paper
• Two-year real-world retrospective safety evaluation with onabotulinumtoxinA across multiple therapeutic indications: findings from the SYNCHRONIZE study.

  2025cites this paper
• Decades of Scientific Data and Global Media Reporting on Complications in Non-surgical Aesthetic Treatments for a Transparent Safety Profile: Kissing Snow White Awake

  2025cites this paper
• Optimal Practices in the Delivery of Aesthetic Medical Care to Patients on Immunosuppressants and Immunomodulators: A Systematic Review of the Literature.

  2024cites this paper
• Exploring Nonresponse to Botulinum Toxin in Aesthetics: Narrative Review of Key Trigger Factors and Effective Management Strategies

  2024cites this paper
• Update on Non-Interchangeability of Botulinum Neurotoxin Products

  2024cites this paper
• Phase I Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-858 for Treatment of Glabellar Lines

  2024cites this paper
• Immunogenicity of Botulinum Toxin Type A in Different Clinical and Cosmetic Treatment, a Literature Review

  2024cites this paper
• Efficacy of Botulinum Type A Injection for the Treatment of Postherpetic Neuralgia and Pruritus Persisting for More Than Four Years—A Case Report

  2024cites this paper
• Response to Botulinum Toxin Type-A in Patients with Refractory Chronic Migraine

  2024cites this paper
• Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact

  2023cites this paper
• The Place of Botulinum Toxin in Spastic Hemiplegic Shoulder Pain after Stroke: A Scoping Review

  2023cites this paper
• Microtoxin for Improving Pore Size, Skin Laxity, Sebum Control, and Scars: A Roundtable on Integrating Intradermal Botulinum Toxin Type A Microdoses Into Clinical Practice

  2023cites this paper
• Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX®) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis

  2023influential citation
• Medicamentos bioterapéuticos: uso de toxinas botulínicas en la era de biosimilares

  2023cites this paper
• Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact

  2023cites this paper
• Botulinum Toxin Type A Immunogenicity across Multiple Indications: An Overview Systematic Review

  2022cites this paper
• A comprehensive review on the history, uses, and safety of onabotulinum toxin type A (Botox)

  2022cites this paper
• Incobotulinum toxin A: A shelf‐stable, low‐molecular‐weight formulation

  2022cites this paper
• Emerging Trends in Botulinum Neurotoxin A Resistance: An International Multidisciplinary Review and Consensus

  2022cites this paper
• Assessment of Electromyographic Changes in a Patient with Masseter Hypertrophy and Muscle Pain after Botulinum Injections: A Case Report and 5 Months Follow-up.

  2022cites this paper
• Creating Lift in the Lower Face With Botulinum Toxin A Treatment: An Anatomical Overview With Videos and Case Studies Illustrating Patient Evaluation and Treatment

  2022cites this paper
• Immunogenicity of botulinum toxin

  2022cites this paper
• Surgical Management of Post-FacialParalysis Synkinesis

  2022cites this paper
• Botulinum Toxins

  2022cites this paper
• Botulinum toxins in cosmetology: clarifications

  2021cites this paper
• Botulinum toxin in neurological clinical practice

  2021cites this paper
• Botulinum Neurotoxins as a Therapeutic

  2021cites this paper
• Response to: Neutralizing Antibodies to Botulinum Toxin Type A Are Rare Following Aesthetic Indications.

  2021cites this paper
• Botulinum Toxins in Medical and Cosmetic Dermatology

  2021cites this paper
• Botulinum Toxin Injections

  2021cites this paper
• Treatment of dystonia

  2021cites this paper
• Spasticity

  2021cites this paper
• Antibody Development in Patients Treated Long-Term With OnabotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm

  2021cites this paper
• Immunogenicity to Botulinum Toxin Type A: A Systematic Review With Meta-Analysis Across Therapeutic Indications.

  2021cites this paper
• High-Dose Neuromodulators: A Roundtable on Making Sense of the Data in Real-World Clinical Practice

  2021cites this paper
• Axillary Botulinum Toxin Injection for the Treatment of Moderate to Severe Hyperhidrosis

  2021cites this paper
• To evaluate the effect and longevity of Botulinum toxin type A (Botox®) in the management of gummy smile - A longitudinal study upto 4 years follow-up.

  2021cites this paper
• Combined Interventional Treatment of Refractory Chronic Migraine

  2021cites this paper
• Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.

  2020cites this paper
• One-day combined botulinum toxin injections and pulsed radiofrequency of greater occipital nerve for treatment refractory chronic migraine

  2020cites this paper
• Botulinum toxin in facial plastic surgery

  2020cites this paper
• Botulinum Toxins and Soft Tissue Fillers

  2020cites this paper
• Antibody‐induced botulinum toxin treatment failure: A review and novel management approach

  2020cites this paper
• Aplicación de toxina botulínica en estéticas

  2020cites this paper
• Atlas of Surgical Therapy for Migraine and Tension-Type Headache

  2020cites this paper
• Botulinumtoxin in der Neurologie

  2020cites this paper
• Cervical dystonia - improving the effectiveness of botulinum toxin therapy.

  2020cites this paper
• High Dosage of Botulinum Toxin Type A in Adult Subjects with Spasticity Following Acquired Central Nervous System Damage: Where Are We at?

  2020cites this paper
• Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy

  2020cites this paper
• Focal Dystonia and Botulinum Toxin: Our Experience with IncobotulinumtoxinA

  2019cites this paper
• Botulinum Neurotoxin: Basic Facts, Physiology and Pharmacology

  2019cites this paper
• Clinical evaluation of botulinum toxin A in the management of temporomandibular myofascial pain.

  2019cites this paper
• Current Concepts in Assessment and Management of Spasticity

  2019cites this paper
• Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review.

  2019cites this paper
• Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy

  2019cites this paper
• Development of inhibition ELISA to detect antibody-induced failure of botulinum toxin a therapy in cosmetic indications.

  2019cites this paper
• Neurostimulation-guided Anal Intrasphincteric Botulinum Toxin Injection in Children With Hirschsprung Disease

  2019cites this paper
• Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients.

  2019cites this paper
• Immunogenicity Associated with Botulinum Toxin Treatment

  2019influential citation
• Spasticity.

  2019cites this paper
• Botulinum Toxin: Pharmacology and Injectable Administration for the Treatment of Primary Hyperhidrosis.

  2019cites this paper
• Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4‐Year Clinical Experience

  2019cites this paper
• OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.

  2018cites this paper
• Animal Models in Chronic Daily Headache (CDH) and Pathophysiology of CDH

  2018cites this paper
• Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis

  2018cites this paper
• Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

  2018cites this paper
• High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy

  2018cites this paper
• Dystonia: diagnosis and management

  2018cites this paper
• Surgical Management of Postparalysis Facial Palsy and Synkinesis.

  2018cites this paper
• A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults.

  2018cites this paper
• Relevance of Immunoresistance to Botulinum Therapy

  2018cites this paper
• Botulinum Toxin: From Molecule to Medicine

  2017cites this paper
• Safety of available and emerging drug therapies for hyperhidrosis

  2017cites this paper
• Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long‐term extension study

  2017cites this paper
• Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy

  2017cites this paper
• Botulinum Toxin Therapy for Parkinson's Disease

  2017cites this paper
• Botulinum Toxin Injection

  2017cites this paper
• Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules.

  2017cites this paper
• Complications of Botulinum Toxin and Facial Fillers

  2017cites this paper
• Treatment of the Glabella

  2017cites this paper
• Treatment of the Forehead

  2017cites this paper
• Rehabilitation management of post-stroke spasticity

  2017cites this paper
• Systematic analysis of botulinum neurotoxin type A immunogenicity in clinical studies

  2017cites this paper
• Botulinum Toxin in Aesthetic Medicine: Myths and Realities

  2017influential citation
• Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder

  2017cites this paper
• Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration

  2017cites this paper
• Overview of Botulinum Toxins for Aesthetic Uses.

  2016cites this paper
• Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity

  2016cites this paper
• Anatomical Regional Targeted (ART) BOTOX Injection Technique: A Novel Paradigm for Migraines and Chronic Headaches

  2016cites this paper
• Pharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity

  2016cites this paper
• Botulinum Toxin in the Treatment of Pediatric Upper Limb Spasticity

  2016cites this paper
• Clinical Relevance of Immunoresistance to Botulinum Therapy

  2016cites this paper
• High Botulinum Toxin‐Neutralizing Antibody Prevalence Under Long‐Term Cervical Dystonia Treatment

  2016cites this paper
• Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients.

  2016influential citation
• Long‐Term Use and Safety of Migraine Preventive Medications

  2016cites this paper
• Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea

  2016cites this paper
• Clinical Relevance of Immunoresistance to Botulinum Therapy Clinical Relevance of Immunoresistance to Botulinum Therapy

  2016cites this paper
• Gezielte Diagnose und leitliniengerechte Therapie von Dystonien

  2016cites this paper
• Pain Management of Herpes Zoster

  2016cites this paper